Activity of paromomycin against Leishmania amazonensis: Direct correlation between susceptibility in vitro and the treatment outcome in vivo
Sign Up to like & getrecommendations! Published in 2020 at "International Journal for Parasitology: Drugs and Drug Resistance"
DOI: 10.1016/j.ijpddr.2020.08.001
Abstract: Paromomycin is an aminoglycoside antibiotic approved in 2006 for the treatment of visceral leishmaniasis caused by Leishmania donovani in Southeast Asia. Although this drug is not approved for the treatment of visceral and cutaneous leishmaniasis… read more here.
Keywords: leishmaniasis; amazonensis; susceptibility; vivo ... See more keywords